Alzheimer’s disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ? The patients met the diagnostic criteria of AD-induced MCI issued by the National Institute on Aging and Alzheimer's disease (NIA-AA) in 2011. (2) patients complained of cognitive changes, or reported by caregivers or clinicians; (3) one or more cognitive domains were impaired, including memory, executive function, attention, language and visuospatial function, especially episodic memory. ? Auditory speech learning test (AVLT) showed that the patient had objective memory decline. ? The MoCA score was less than 26, and the CDR score was 0.5. ? MMSE score was more than 20. ? They had independent activities of daily living, no evidence of serious influence on social or occupational function, and their ADL score was less than 26. ? Willing and able to complete all the content of this study, including neuropsychological assessment and blood collection Relevant indicators, electrophysiological and neuroimaging examinations were performed, and longitudinal follow-up was agreed. ? Agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: ? The presence of a history of stroke temporally related to the onset or worsening of cognitive impairment, or the presence of multiple or extensive cerebral infarction or severe white matter hyperintensities; ? with the core features of Lewy body disease; ? with the significant characteristics of behavioral variant frontotemporal lobar degeneration. (4) significant features of primary progressive semantic aphasia or primary progressive nonfluent/grammatical aphasia. And 5) there were other evidence that significantly affected cognitive function, such as neurological diseases, non-neurological diseases or drug abuse history. ? Dysarthria, depression and mental illness affect emotional expression. ? Patients with contraindications of magnetic resonance imaging, visual and hearing impairment could not cooperate to complete all examination items. ? There is a bleeding tendency such as thrombocytopenia and abnormal coagulation function, or any disease that cannot be treated with acupuncture and intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment, MoCA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Dementia Rating,CDR;Mini-Mental State Examination, MMSE;Alzheimer’s Disease Assessment Scale-Cognitive Subscale,ADAS-cog;Auditory Verb Learning Test,AVLT;Rey Complex Figure Test-Delay Recall, RCFT-DR;Rey Complex Figure Test, RCFT;Clock drawing test, CDT; Animal Fluency Test, AFT;Boston Naming Test, BNT;Chinese Modified Version of the Trail Making Test-A, TMT-A; Chinese Modified Version of the Trail Making Test-B, TMT-B;Neuropsychiatric Inventory,NPI;Hamilton Rating Scale for Depression,HAMD;Hamilton Anxiety Rating Scale,HAMA;Pittsburgh sleep quality index, PSQI;Cohen-Mansfield Agitation Inventory, CMAI;Modified Apathy Evaluation Scale,MAES;Activities of Daily Living, ADL;AD neuropathological proteins;Neuroimmune inflammatory factors;neurotrophin;neurotransmitter; event-related potential P300; rs-fMRI; | — |
Countries
China
Contacts
Beijing Tiantan Hospital, Capital Medical University